Atrial fibrillation is the a widespread heart problem which is an abnormal heart rhythm. It is generally linked with palpitation, fainting, chest pain. The researchers are still working to calculate the cause of this disease.
For several years, this disease is treated through the drug digoxin, which is pulled from the foxglove plant.
Recently, a study has revealed the fact that Digoxin can increase the mortality rate in the patients who is newly diagnosed from Atrial fibrillation. Even if a person remains untreated than there are probabilities that he can survive more as compared to the patient who takes digoxin. It immediately escalates the hazard of heart stroke and heart failure in the patients.
This survey has been carried out between 2003 and 2008 and demonstrated that 70 percent of the 23 percent patients who were recommended digoxin continued to hold it for another twelve months. On the whole there were almost 122465 patients included in this experiment and eventually they helped the experts in the formation of a conclusion.
As stated by the The American Heart Association and American College of Cardiology Foundation doctors should not consider digoxin as the first therapy to cure this ailment. Though it cannot be said that digoxin is entirely useless, it can be extremely constructive for the patients with heart failure.
According to Turakhia, the study author this report filled the chief evidence gap in the management of atrial fibrillation. Its outcome is not as the usual experiment of atrial fibrillation since digoxin was used for decades for the treatment of Afib patients. The study indicates that almost 3 percent patients are more at risk of dying due to digoxin.
Michael Turner
